Affordable Access

deepdyve-link
Publisher Website

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Authors
  • Lamanna, Nicole1
  • Jurcic, Joseph G
  • Noy, Ariela
  • Maslak, Peter
  • Gencarelli, Alison N
  • Panageas, Katherine S
  • Heaney, Mark L
  • Brentjens, Renier J
  • Golde, David W
  • Scheinberg, David A
  • Zelenetz, Andrew D
  • Weiss, Mark A
  • 1 Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Feb 01, 2009
Volume
27
Issue
4
Pages
491–497
Identifiers
DOI: 10.1200/JCO.2008.16.4459
PMID: 19075280
Source
Medline
License
Unknown

Abstract

Sequential therapy with F-->C-->R yields improvement in quality of response, with many patients achieving a PCR-negative state.

Report this publication

Statistics

Seen <100 times